We protect your health through science
Investigation
Bacterial Genetics
Research projects
Content with Investigacion .
- Título: Desvelando la genómica de las bacterias anaerobias procedentes de bacteriemias
Referencia Proyecto: PID202-1127477OB-I00-MPY 302/22.
Entidad financiador: Agencia Estatal de Investigación.
Fechas de ejecución: 2023-2026
Financiación 108.900 €.
Investigadora principal: Sylvia Valdezate
- Título: Plataformas MALDI-TOF/CMI SENSITITRETM Personal Técnico Apoyo
Referencia: PTA2019-016623-I.
Entidad Financiadora: Agencia Estatal de Investigación.
Fechas ejecución 12/2020-11/2023
Investigadora principal: Sylvia Valdezate
- Título: Elementos genéticos móviles protagonistas en la evolución de los serotipos pandémicos M1 y M89 de Streptococcus pyogenes en el síndrome del shock tóxico y otras infecciones invasivas
Referencia: (MPY 377/18).
Entidad financiadora: Instituto de Salud Carlos III. Agencia Estatal de Investigación en Salud Intramural (AESI).
Fechas de ejecución: 11/2018-12/2022.
Financiación: 40.000 €.
Investigadoras principales: Pilar Villalón. Co-IP Sylvia Valdezate.
- Título: Plataformas genéticas y su influencia en la resistencia a co-trimoxazol, macrólidos y tetraciclina en Nocardia spp.
Referencia: MPY 1278/15
Entidad financiadora: Instituto de Salud Carlos III. Agencia Estatal de Investigación en Salud Intramural (AESI).
Fechas de ejecución: 2015-2017.
Financiación: 88.141,8 €.
Investigadora principal: Sylvia Valdezate
- Título: Filogenia y caracterización de mecanismos moleculares de resistencia en Nocardia spp.
Referencia: MPY 1446/11
Entidad financiadora: Instituto de Salud Carlos III. Fondo de Investigación Sanitaria (AES). ()
Fechas de ejecución: 04/2012-10/2015
Financiación: 115.457 €.
Investigadora principal: Sylvia Valdezate.
- Título: Iberian network of laboratories of biological alert. Accreditation of methods for detection highly pathogenic agents (IB-BIOALERTNET).
Entidad financiadora: COMISIÓN EUROPEA HOME/2012/ISEC/AG/CBRN/4000003810. (Instituto de Salud Carlos III (VISAVET, IVIA, INSA, INIAV))
Referencia: SAFI 1132/13-7.
Fecha de ejecución: 2013-2015.
Financiación: 699.175 €.
Tipo de participación: Miembro del equipo investigador.
- Título: EQUATOX Project Establishment of Quality Assurances for theDetection of Biological Toxins of potential Bioterrorism risk.
Entidad financiadora y convocatoria: Seven Framework Programme for Research FP7-SECURITY. (Robert Koch-Institut Berlin Alemania).
Referencia: SEC-2011.5.4-1.
Fechas de ejecución: 2012-2014.
Publications
High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity.
Pérez-García F, Martin-Vicente M, Rojas-García RL, Castilla-García L, Muñoz-Gomez MJ, Hervás Fernández I, González Ventosa V, Vidal-Alcántara EJ, Cuadros-González J, Bermejo-Martin JF, Resino S#, Martínez I#. High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity. J Infect Dis. 2022 Mar 15;225(6):977-982. doi: 10.1093/infdis/jiab604. PMID: 34910814 (A; FI= 7.759; Q1 Microbiology; JCR 2021).
PUBMEDNeighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study.
Álvaro-Meca A, Sepúlveda-Crespo D#, Resino R, Ryan P, Martínez I#, Resino S#. Neighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study. Environ Health. 2022 Nov 8;21(1):107. doi: 10.1186/s12940-022-00928-x. PMID: 36348411.
PUBMEDDiagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis.
Sepúlveda-Crespo D, Treviño-Nakoura A, Bellon JM, Jiménez-Sousa MA, Ryan P, Martínez I#, Fernández-Rodríguez A#, Resino S#. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis. J Clin Microbiol. 2023 Jan 26; 61(1):e0133122. doi: 10.1128/jcm.01331-22. PMID: 36537787.
PUBMEDHCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
Brochado-Kith Ó, Martínez I*, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S*. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol. 2021 Aug 23;12:723196. doi: 10.3389/fimmu.2021.723196. eCollection 2021.PMID: 34497613 (A; FI= 8.786; Q1 Immunology; JCR 2021).
PUBMEDHIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
Ryan P, Valencia J, Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ, Muñoz-Rivas N, Canorea I, Vázquez-Morón S (‡), Resino S (‡ *). HIV screening and retention in care in people who use drugs in Madrid, Spain: A prospective study. Infect Dis Poverty. 2021; 10(1): 111. (A; FI= 10.49; D1, Tropical Medicine; JCR 2021). PMID: 34412695. DOI: 10.1186/s40249-021-00894-5.
PUBMEDObesity-related SNPs and weight gain following first-line antiretroviral therapy.
Berenguer J (*), Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, Roca C, González-García J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-related SNPs and weight gain following first-line antiretroviral therapy. Clin Inf Dis. 2023; In press. (A; FI= 20.99; D1, Infectious Diseases; JCR 2021).
PUBMED DOIMild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study.
García-Broncano P, Medrano LM, Berenguer J, Brochado O, González-García J, Jiménez-Sousa MA, Quereda C, Sanz J, Téllez MJ, Díaz L, Jiménez JL, Muñoz-Fernández MA, Resino S (*). Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect 2020; 80(1):99-110. (A; FI= 6.07; Q1, Infectious Diseases; JCR 2020). PMID: 31585189. DOI: 10.1016/j.jinf.2019.09.020.
PUBMEDEvaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Rueda C, Puig-Asensio M, Guinea J, Almirante B, Cuenca-Estrella M, Zaragoza O; CANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. Clin Microbiol Infect. 2017 Jan;23(1):49.e1-49.e8.
PUBMED DOIIdentification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp
Rossi SA, de Oliveira HC, Agreda-Mellon D, Lucio J, Mendes-Giannini MJS, García-Cambero JP, Zaragoza O. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother. 2020 Mar 24;64(4):e01921-19. PMCID: PMC7179310.
PUBMED DOIParadoxical Growth of Candida albicans in the Presence of Caspofungin Is Associated with Multiple Cell Wall Rearrangements and Decreased Virulence
Rueda C, Cuenca-Estrella M, Zaragoza O. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother. 2014;58(2):1071-83. PMCID: PMC3910852.
PUBMED DOIHCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients.
Brochado-Kith O, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A (‡), Jiménez-Sousa MA (‡), Resino S (‡ *). HCV cure with direct-acting antivirals improves liver and immunological markers in HIV/HCV-coinfected patients. Front immunol. 2021; 12:723196. (A; FI= 8.79; Q1, Immunology; JCR 2021). PMID: 34497613. DOI: 10.3389/fimmu.2021.723196.
PUBMEDCryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella
Trevijano-Contador N, Herrero-Fernández I, García-Barbazán I, Scorzoni L, Rueda C, Rossi SA, García-Rodas R, Zaragoza O. Cryptococcus neoformans induces antimicrobial responses and behaves as a facultative intracellular pathogen in the non mammalian model Galleria mellonella. Virulence. 2015;6(1):66-74. PMCID: PMC4603429.
PUBMED DOIThe formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses
García-Barbazán I, Trevijano-Contador N, Rueda C, de Andrés B, Pérez-Tavárez R, Herrero-Fernández I, Gaspar ML, Zaragoza O. The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses. Cell Microbiol. 2016 Jan;18(1):111-24.
PUBMED DOIPrevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey.
• Estirado Gómez A, Justo-Gil S, Limia A, Avellón A, Arce-Arnáez A, González-Rubio R, Diaz A, Del Amo J; Prevalence and undiagnosed fraction of hepatitis C infection in 2018 in Spain: results from a national population-based survey. Sci Rep. 2018 Jan 30;8(1):1858.
PUBMED DOIComparative Analysis of Aspergillus fumigatus Strains: The Reference Genome as a Matter of Concern.
Buitrago MJ, Martín-Gómez T. Timely Diagnosis of Histoplasmosis in Non-endemic Countries: A Laboratory Challenge. Front Microbiol. 2020 Mar 24; 11:467. doi: 10.3389/fmicb.2020.00467. eCollection 2020. PMID: 32269555.
PUBMED DOIIdentification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene.
Matamala N, Aggarwal N, Iadarola P, Fumagalli M, Gomez-Mariano G, Lara B, Martinez MT, Cuesta I, Stolk J, Janciauskiene S, Martinez-Delgado B. Identification of Novel Short C-Terminal Transcripts of Human SERPINA1 Gene. PLoS One. 2017 Jan 20;12(1):e0170533.
PUBMED DOIA case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015.
Jané, M., Vidal, M.J., Camps, N., Campins, M., Martínez, A., Balcells, J., Martin-Gomez, M.T., Bassets, G., Herrera-Leon, S., Foguet, A., Maresma, M., Follia, N., Uriona, S., Pumarola, T. A case of respiratory toxigenic diphtheria: Contact tracing results and considerations following a 30-year disease-free interval, Catalonia, Spain, 2015. (2018) Eurosurveillance, 23 (13).
PUBMED DOIDevelopment of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans
Sánchez, S., Llorente, M.T., Echeita, M.A., Herrera-León, S. Development of three multiplex PCR assays targeting the 21 most clinically relevant serogroups associated with Shiga toxin-producing E. coli infection in humans (2015) PLoS ONE, 10 (1).
PUBMED DOIShiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household
Sánchez, S., Cenoz, M.G., Martín, C., Beristain, X., Llorente, M.T., Herrera-León, S. Cluster investigation of mixed O76:H19 Shiga toxin-producing Escherichia coli and atypical enteropathogenic E. coli infection in a Spanish household (2014) Epidemiology and Infection, 142 (5), pp. 1029-1033.
PUBMED DOIContent with Investigacion .
-
Mónica Valiente Novillo
Técnico de laboratorio. Convocatoria empleo juvenial (PEJ-2021-TL_BMD-21100)
-
-
-
-
-
Noelia Castrillo Garrido
Técnico de Laboratorio. Contratada de Proyecto PID2021-127477OB-I00 (AEI)
ORCID code: 0000-0003-1676-9693
List of staff
Additional Information
Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.
Streptococcus pneumoniae is a human pathogen that, despite the development of vaccines, continues to be an important cause of mortality and morbidity. We investigate the mechanisms of antibiotic resistance in this bacterium. On the one hand by identifying new therapeutic targets and on the other hand by investigating the molecular basis of the action of antibiotics already used in clinical practice (the fluoroquinolones levofloxacin and moxifloxacin) or not yet used (seconeolitsine). For this purpose, we used a multidisciplinary analysis involving genomics, transcriptomics and proteomics to understand the organization of the S. pneumoniae chromosome and the identification of the factors that stabilize this organization, including ncRNAs. Changes in the level of global supercoiling, either by inhibition of gyrase (decrease) or by inhibition of topoisomerase I (increase) alter the transcriptome. The modulated genes are located in domains, whose genes show specific functional characteristics. The aim is to identify new factors essential for S. pneumoniae physiology and to characterize transcriptional regulation in response to topological stress. In addition, RNA interference technology and CRISPR systems will be used as novel antibacterials. These studies will establish the bases for translational research aimed at the development of new therapeutic targets for the treatment of pneumococcal diseases.